Company intelligence / Profile preview

NanoVation Therapeutics

Vancouver, British Columbia, Canadananovationtx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company's lcLNP technology has demonstrated the ability to deliver nucleic acids to various cell types beyond the liver in preclinical studies, with improved potency, safety and stability compared to conventional systems.

Therapeutic areas: Rare DiseasesCardiovascularMetabolic Disorders
Modalities: Genetic medicinesRNA therapiessiRNAmRNApDNANucleic acid delivery
Industry: Drug Discovery Services

Beyond the preview

Go deeper on NanoVation Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoVation Therapeutics.